ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biologics

WuXi invests $60 million in Massachusetts

by Jean-François Tremblay
June 17, 2018 | APPEARED IN VOLUME 96, ISSUE 25

 

Chinese contract manufacturer WuXi Biologics is spending $60 million in Worcester, Mass., to build a plant that will produce biologics and employ as many as 150 people. With a total bioreactor capacity of 4,500 L, the site will primarily employ single-use bioreactors but will also implement a continuous process that WuXi claims to have developed. WuXi has been busily expanding commercial production in recent months with investments totaling hundreds of millions of dollars in new plants in Ireland, Singapore, and China.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment